医学
安慰剂
肝硬化
随机对照试验
非酒精性脂肪肝
肝活检
纤维化
人口
慢性肝病
临床终点
内科学
脂肪性肝炎
脂肪肝
胃肠病学
活检
病理
疾病
替代医学
环境卫生
作者
Stephen A. Harrison,Pierre Bédossa,Cynthia D. Guy,Jörn M. Schattenberg,Rohit Loomba,Rebecca Taub,Dominic Labriola,Sam E. Moussa,Guy Neff,Mary E. Rinella,Quentin M. Anstee,Manal F. Abdelmalek,Zobair M. Younossi,Seth J. Baum,Sven Francque,Michael Charlton,Philip N. Newsome,Nicolas Lanthier,Ingolf Schiefke,Alessandra Mangia
标识
DOI：10.1056/nejmoa2309000
摘要
Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
eric888
嘻嘻哈哈
GingerF
Criminology34
my
LPPQBB
tuanheqi
瓜瓜
HaCat
changping
nenoaowu
Perry
MchemG
ukz37752
千早爱音
遇上就这样吧
求求大家帮帮我
哈基米德
竹筏过海
FashionBoy
浮浮世世
小夏饭桶
GPTea
皖公网安备34019202002308
